IFLR Quotes Eric Wu on China Life Sciences Companies Facing Delisting from U.S. Exchanges

In The News
March 29, 2022

A March 22 article by International Financial Law Review (IFLR) examines how under the U.S. Public Company Accounting Oversight Board’s (PCAOB) rules, hundreds of foreign public companies face delisting from trading on U.S. exchanges by the U.S. Securities and Exchange Commission (SEC) due to lack of compliance with auditing requirements. With more than 200 US-listed Chinese companies potentially impacted, in the piece titled “US-listed Chinese companies contemplate next steps,” life sciences partner Eric Wu in discusses this issue in relation to companies in the China life sciences space.